Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review (Q27010547)

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Olaywi M

1

1 reference

Bhatia T

series ordinal

2

1 reference

Anand S

series ordinal

3

1 reference

Singhal S

series ordinal

4

1 reference

language of work or name

1 reference

December 2013

1 reference

Hepatobiliary & Pancreatic Diseases International

published in

1 reference

volume

12

1 reference

issue

6

1 reference

page(s)

584-8

1 reference

Nonalcoholic fatty liver disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Selection and outcome of living donors for adult to adult right lobe transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Prevalence and Predictors of Asymptomatic Liver Disease in Patients Undergoing Gastric Bypass Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Clinical spectrum and therapy of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

The role of incretins in glucose homeostasis and diabetes treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2813%2960092-2

7 January 2021

10.1016/S1499-3872(13)60092-2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2450156

2450156

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference